Scientists test Next-Gen mRNA flu shot in first human trial
NCT ID NCT05945485
Summary
This is an early-stage study to test the safety and immune response of a new mRNA flu vaccine in healthy adults. Up to 50 participants, aged 18-49, will receive two doses of the experimental vaccine or one dose of a standard flu shot for comparison. The main goal is to see if the vaccine is safe and to find the right dose before testing it in larger groups.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INFLUENZA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Iowa - Infectious Disease Clinic
Iowa City, Iowa, 52242, United States
Conditions
Explore the condition pages connected to this study.